Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. It is also developing ATA188 and autologous ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product to treat Wilms tumor 1; and ATA230, which is Phase II clinical trials for refractory cytomegalovirus. In addition, the company is developing ATA368 that is under preclinical development for HIV and cancers. It has license agreements with Memorial Sloan Kettering Cancer Center and Amgen, Inc.; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with Moffitt Cancer Center. The company was founded in 2012 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone650-278-8930
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees311
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions
What is Atara Biotherapeutics' stock symbol?
Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."
How were Atara Biotherapeutics' earnings last quarter?
Atara Biotherapeutics Inc (NASDAQ:ATRA) issued its quarterly earnings data on Tuesday, February, 26th. The biotechnology company reported ($1.75) EPS for the quarter, missing the Zacks' consensus estimate of ($1.31) by $0.44. View Atara Biotherapeutics' Earnings History.
When is Atara Biotherapeutics' next earnings date?
What price target have analysts set for ATRA?
7 analysts have issued 1-year target prices for Atara Biotherapeutics' shares. Their forecasts range from $23.00 to $70.00. On average, they expect Atara Biotherapeutics' stock price to reach $51.20 in the next year. This suggests a possible upside of 36.8% from the stock's current price. View Analyst Price Targets for Atara Biotherapeutics.
What is the consensus analysts' recommendation for Atara Biotherapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Atara Biotherapeutics.
What are Wall Street analysts saying about Atara Biotherapeutics stock?
Here are some recent quotes from research analysts about Atara Biotherapeutics stock:
- 1. According to Zacks Investment Research, "Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. " (3/4/2019)
- 2. Mizuho analysts commented, "We note that this is not the first time the company has put an ATM in place." (2/26/2019)
Has Atara Biotherapeutics been receiving favorable news coverage?
Media stories about ATRA stock have trended positive this week, according to InfoTrie. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Atara Biotherapeutics earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future.
Who are some of Atara Biotherapeutics' key competitors?
Some companies that are related to Atara Biotherapeutics include Spark Therapeutics (ONCE), argenx (ARGX), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX) and Rubius Therapeutics (RUBY).
What other stocks do shareholders of Atara Biotherapeutics own?
Who are Atara Biotherapeutics' key executives?
Atara Biotherapeutics' management team includes the folowing people:
- Dr. Isaac E. Ciechanover, Pres, CEO & Director (Age 48)
- Mr. Joseph Newell, Exec. VP & Chief Technical Operations Officer (Age 49)
- Dr. Derrell D. Porter, Sr. VP & Global Commercial Head (Age 48)
- Mr. Utpal Koppikar, Chief Financial Officer
- Dr. Christopher M. Haqq, Exec. VP of R&D & Chief Scientific Officer (Age 53)
Who are Atara Biotherapeutics' major shareholders?
Atara Biotherapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (11.55%), BlackRock Inc. (7.70%), Eagle Asset Management Inc. (3.53%), Norges Bank (1.30%), Northern Trust Corp (1.14%) and Geode Capital Management LLC (1.09%). Company insiders that own Atara Biotherapeutics stock include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Gad Soffer, Heather D Turner, Isaac E Ciechanover, Joe Newell, Joel S Marcus, John Mcgrath, Matthew K Fust, Mitchall G Clark and Utpal Koppikar. View Institutional Ownership Trends for Atara Biotherapeutics.
Which major investors are selling Atara Biotherapeutics stock?
ATRA stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Eagle Asset Management Inc., MetLife Investment Advisors LLC, Squarepoint Ops LLC, Principal Financial Group Inc., New York State Common Retirement Fund, Flinton Capital Management LLC and Northern Trust Corp. Company insiders that have sold Atara Biotherapeutics company stock in the last year include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Isaac E Ciechanover, Joe Newell, Joel S Marcus, Matthew K Fust and Mitchall G Clark. View Insider Buying and Selling for Atara Biotherapeutics.
Which major investors are buying Atara Biotherapeutics stock?
ATRA stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Canada Pension Plan Investment Board, FMR LLC, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Geode Capital Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Atara Biotherapeutics.
How do I buy shares of Atara Biotherapeutics?
Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Atara Biotherapeutics' stock price today?
One share of ATRA stock can currently be purchased for approximately $37.44.
How big of a company is Atara Biotherapeutics?
Atara Biotherapeutics has a market capitalization of $1.73 billion. The biotechnology company earns $-230,700,000.00 in net income (profit) each year or ($5.27) on an earnings per share basis. Atara Biotherapeutics employs 311 workers across the globe.
What is Atara Biotherapeutics' official website?
How can I contact Atara Biotherapeutics?
Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930.
MarketBeat Community Rating for Atara Biotherapeutics (NASDAQ ATRA)
MarketBeat's community ratings are surveys of what our community members think about Atara Biotherapeutics and other stocks. Vote "Outperform" if you believe ATRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
